This information is not intended for Healthcare Professionals operating from or located in the USA.

What is it?

IMUKIN contains a substance called recombinant human interferon gamma-1b. Interferons are so-called immunomodulators. These are small proteins that can stimulate the body’s immune system defences. They protect against micro-organisms (e.g. bacteria, viruses and fungi) that can cause diseases.

IMUKIN is for use by patients with chronic granulomatous disease (CGD). CGD is a defect in the metabolism of neutrophils, a type of white blood cell. These normally kill invading bacteria or fungi. The defect with CGD makes neutrophils less able to prevent infections. IMUKIN is used to reduce the number of serious infections that may occur with this disease.

IMUKIN is also used in patients with severe, progressive marble bone disease (osteopetrosis). This is an inherited defect in bone cells, which leads to excessive, abnormal bone growth. It also affects the bone marrow and the blood cells that are usually formed in it. As a result, patients with osteopetrosis are also at risk of serious infections.

Marketing Authorisations

Please click on a country from the list below.  You will be directed to the regulatory agency website for the country you have selected, where you can find the registered prescribing information. The marketing authorisations are either held by Clinigen or our local partner.

Important Safety Information